Introduction {#Sec1}
============

Infections caused by multi-drug resistant (MDR) Gram-negative (GN) organisms in critically ill patients are a therapeutic challenge. Few therapeutical options are available.

Objectives {#Sec2}
==========

The administration of high-dose aminoglycoside (HDA) therapy coupled with high-flow continuous veno-venous hemodiafiltration (CVVHDF) could allow required high drug peaks to be achieved with reduced toxicity.

Methods {#Sec3}
=======

All adult patients present on the intensive care unit (ICU) between October 2009 and July 2014 who had MDR-GN sepsis were considered for HDA and high-flow (\>45 mL/kg/h) CVVHDF when an isolated pathogen was at least partially sensitive to aminoglycosides and the patient\'s condition was not improving with conventional therapy. Optimal antibacterial activity was defined as a peak concentration of at least 8 times the minimal inhibitory concentration.

Results {#Sec4}
=======

Fifteen patients infected with MDR-GN pathogens (11 with Pseudomonas aeruginosa; 10 with abdominal and 5 with respiratory infections) were treated with amikacin (n = 11), gentamicin (n = 3) or tobramycin (n = 1) and high-flow CVVHDF. A favorable clinical response was observed in 8 (53%) patients, including 3 in whom microbial eradication was obtained. Six patients were discharged alive from the ICU, and five from the hospital. No renal toxicity was observed.

Conclusions {#Sec5}
===========

In this cohort of septic patients with MDR-GN infections, HDA combined with high-flow CVVHDF represented a valuable therapeutic option. The effectiveness of this approach should be further evaluated in larger studies.
